IL-17 produced from Th17 lymphocytes recruits CD11b+ Gr1+ immature myeloid cells to the tumor site, which induces granulocyte colony-stimulating factor (G-CSF) to promote tumor resistance to anti-angiogenic therapy (VEGF inhibition) [109]. This evidence concerns the gene IL17A and neoplasm.